MARKET

MLND

MLND

Millendo Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.430
+0.030
+2.14%
After Hours: 1.430 0 0.00% 19:58 04/08 EDT
OPEN
1.400
PREV CLOSE
1.400
HIGH
1.430
LOW
1.300
VOLUME
1.30M
TURNOVER
--
52 WEEK HIGH
17.34
52 WEEK LOW
1.260
MARKET CAP
26.12M
P/E (TTM)
-0.4405
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average MLND stock price target is 4.500 with a high estimate of 6.00 and a low estimate of 2.000.

EPS

MLND News

More
  • Benzinga's Top Upgrades, Downgrades For April 7, 2020
  • Benzinga · 1d ago
  • 10 Biggest Price Target Changes For Tuesday
  • Benzinga · 1d ago
  • The Daily Biotech Pulse: Sanofi, Regeneron Finalize Praluent Restructuring, Natus Pre-Announces Q1 Shortfall, Alcon To Delay Dividend Initiation
  • Benzinga · 1d ago
  • Mid-Afternoon Market Update: Dow Surges Over 1200 Points; Millendo Therapeutics Shares Plummet
  • Benzinga · 2d ago

Industry

Biotechnology & Medical Research
+3.06%
Pharmaceuticals & Medical Research
+2.82%

Hot Stocks

Symbol
Price
%Change

About MLND

Millendo Therapeutics, Inc., formerly OvaScience, Inc. is a late-stage biopharmaceutical company. The Company is focused on developing novel treatments for orphan endocrine diseases. The Company is focused on advancing two product candidates to treat three indications. Its advanced product candidate, livoletide (AZP-531), is a potential treatment for Prader-Willi syndrome (PWS), which is a rare and complex genetic endocrine disease characterized by hyperphagia, or insatiable hunger. It is also developing nevanimibe (ATR-101) with a primary focus on treating patients with classic congenital adrenal hyperplasia (CAH), which is a rare, monogenic adrenal disease that requires lifelong treatment with exogenous cortisol.
More

Webull offers kinds of Millendo Therapeutics Inc stock information, including NASDAQ:MLND real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MLND stock news, and many more online research tools to help you make informed decisions.